A Phase 1 Study of LNCB74 in Advanced Solid Tumors
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Ovarian Cancer|Breast Cancer|Endometrial Cancer|Biliary Tract Cancer|Non-Small Cell Lung Cancer|Advanced or Metastatic Solid Tumors
DRUG: LNCB74
Evaluate the safety and tolerability of LNCB74, Incidence of AEs, SAEs, AEs meeting protocol defined DLT criteria, AEs leading to discontinuation and death, and laboratory abnormalities per NCI CTCAE v5.0, 24 months|Define a recommended Phase 2 dose (RP2D) of LNCB74, Maximum tolerated dose (MTD), maximum administered dose (MAD) and/or recommended Phase 2 dose (RP2D) of LNCB74, Up to 24 months
Characterize the immunogenicity of LNCB74, Incidence of anti-drug antibodies to LNCB74, 24 months|Objective Response Rate (ORR), Objective Response Rate (ORR) per RECIST v1.1, 24 months|Duration of Response (DOR), Duration of response per RECIST v1.1, 24 months|Disease Control Rate (DCR), Disease control rate per RECIST v1.1, 24 months|Progression Free Survival Rate (PFSR), Progression Free Survival Rate per RECIST v1.1, 6 months|Correlate B7-H4 Expression with Objective Response Rate (ORR), To determine B7-H4 expression by immunohistochemistry in a central lab and correlate B7-H4 expression with Objective Response Rate (ORR), 24 months|Correlate B7-H4 Expression with Duration of Response (DOR), To determine B7-H4 expression by immunohistochemistry in a central lab and correlate B7-H4 expression with Duration of Response (DOR), 24 months|Correlate B7-H4 Expression with Disease Control Rate (DCR), To determine B7-H4 expression by immunohistochemistry in a central lab and correlate B7-H4 expression with Disease Control Rate (DCR), 24 months|Correlate B7-H4 Expression with Progression Free Survival (PFS), To determine B7-H4 expression by immunohistochemistry in a central lab and correlate B7-H4 expression with Progression Free Survival (PFS), 24 months|Progression Free Survival (PFS), Progression Free Survival per RECIST v1.1, 24 months|Time to Peak Drug Concentration (Tmax) of LNCB74, To evaluate the Time to Peak Drug Concentration (Tmax) of LNCB74, Cycle 1 Days 1, 3, 8 and 15; Cycle 3 Days 1, 3, 8 and 15; Day 1 of Cycles 2, 4, 5, 7 and 9|Area Under the Curve (AUC) of LNCB74, To evaluate the Area Under the Curve (AUC) of LNCB74, Cycle 1 Days 1, 3, 8 and 15; Cycle 3 Days 1, 3, 8 and 15; Day 1 of Cycles 2, 4, 5, 7 and 9|Half-life (T1/2) of LNCB74, To evaluate the Half-life (T1/2) of LNCB74, Cycle 1 Days 1, 3, 8 and 15; Cycle 3 Days 1, 3, 8 and 15; Day 1 of Cycles 2, 4, 5, 7 and 9|Maximum Serum Concentration (Cmax) of LNCB74, To evaluate the Maximum Serum Concentration (Cmax) of LNCB74, Cycle 1 Days 1, 3, 8 and 15; Cycle 3 Days 1, 3, 8 and 15; Day 1 of Cycles 2, 4, 5, 7 and 9
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.